Cite
Markovic U, Romano A, Del Fabro V, et al. Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. Front Oncol. 2021;11:624405doi: 10.3389/fonc.2021.624405.
Markovic, U., Romano, A., Del Fabro, V., Bellofiore, C., Bulla, A., Parisi, M. S., Leotta, S., Gentile, M., Cangialosi, C., Vincelli, I., Mineo, G., Rossi, M., Poidomani, M., Uccello, G., Maugeri, C., Mannina, D., Innao, V., Di Raimondo, F., & Conticello, C. (2021). Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. Frontiers in oncology, 11624405. https://doi.org/10.3389/fonc.2021.624405
Markovic, Uros, et al. "Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey." Frontiers in oncology vol. 11 (2021): 624405. doi: https://doi.org/10.3389/fonc.2021.624405
Markovic U, Romano A, Del Fabro V, Bellofiore C, Bulla A, Parisi MS, Leotta S, Gentile M, Cangialosi C, Vincelli I, Mineo G, Rossi M, Poidomani M, Uccello G, Maugeri C, Mannina D, Innao V, Di Raimondo F, Conticello C. Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey. Front Oncol. 2021 Mar 05;11:624405. doi: 10.3389/fonc.2021.624405. eCollection 2021. PMID: 33763359; PMCID: PMC7982826.
Copy
Download .nbib